CIP
TVRD

Chartwell Investment Partners’s Tvardi Therapeutics TVRD Stock Holding History

Chartwell Investment Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-391
Closed -$306K – 439
2021
Q1 		$306K Buy
+391
New +$268K 0.01% 411

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chartwell Investment Partners's TVRD Position: Q2 2021 in Review

Chartwell Investment Partners sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 391 shares — an estimated $306K sold.

Chartwell Investment Partners first reported a position in TVRD in Q1 2021 and held it in 1 quarter. The position peaked at $306K in Q1 2021. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • Chartwell Investment Partners reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Chartwell Investment Partners sold 391 Tvardi Therapeutics shares in Q2 2021, an estimated $306K.
  • Chartwell Investment Partners first reported a position in Tvardi Therapeutics in Q1 2021 and held it in 1 quarter.
  • Chartwell Investment Partners's Tvardi Therapeutics position peaked at $306K in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Chartwell Investment Partners's 13F filing for Q2 2021, filed 19 Jul 2021.